A biotech company that turns the CRISPR gene-editing discovery into medicines for serious inherited diseases. Its first approved therapy, Casgevy, treats sickle cell disease and beta-thalassemia by editing a patient's own blood stem cells. Co-founded in 2013 by Emmanuelle Charpentier — one of the scientists who shared the Nobel Prize for discovering CRISPR — along with Rodger Novak and Shaun Foy, the company takes its name directly from the gene-editing system it commercializes.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +408.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.